Thymidine phosphorylase and dihydropyrimidine dehydrogenase protein expression in colorectal cancer

International Journal of Cancer

Volumn 94, Issue 2, 2001, Pages 297-301

  Collie Duguid, Elaina S R ^a   Johnston, Stephen J ^a   Boyce, Linda ^a   Smith, Nicola ^a   Cowieson, Aaron ^a   Cassidy, James ^a   Murray, Graeme I ^a   McLeod, Howard L ^a  

^a UNIVERSITY OF ABERDEEN   (United Kingdom)

Author keywords

Colorectal cancer; Dihydropyrimidine dehydrogenase; Thymidine phosphorylase

Indexed keywords

DIHYDROPYRIMIDINE DEHYDROGENASE; DNA; PYRIMIDINE; THYMIDINE PHOSPHORYLASE; URACIL;

ARTICLE; CANCER CHEMOTHERAPY; CELL PROLIFERATION; CLINICAL ARTICLE; COLORECTAL CANCER; DNA SYNTHESIS; ENZYME REGULATION; HUMAN; HUMAN TISSUE; LIVER METASTASIS; PRIORITY JOURNAL; PROTEIN EXPRESSION;

COLORECTAL NEOPLASMS; DIHYDROURACIL DEHYDROGENASE (NADP); HUMANS; OXIDOREDUCTASES; THYMIDINE PHOSPHORYLASE;

EID: 0035888165     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/ijc.1462     Document Type: Article

References (27)

1. Scrip world pharmaceutical news
2. Regional and systemic therapies for advanced colorectal carcinoma: Randomised clinical trial results
3. A review of the pharmacology and clinical activity of new chemotherapy agents for the treatment of colorectal cancer
4. Fluoropyrimidines: A critical evaluation
5. The oral fluoropyrimidines in cancer chemotherapy
6. Positive correlation between the efficacy of capecitabine and doxifluridine and the ratio of thymidine phosphorylase to dihydropyrimidine dehydrogenase activities in tumours in human cancer xenografts
7. Preferential activation of capecitabine in tumour following oral administration to colorectal cancer patients
8. High basal level gene expression of thymidine phosphorylase (platelet-derived endothelial cell growth factor) in colorectal tumours is associated with nonresponse to 5-fluorouracil
9. Enhancement of 5-fluorouracil cytotoxicity by human thymidine-phosphorylase expression in cancer cells: In vitro and in vivo study
10. Response to fluorouracil therapy in cancer patients: The role of tumoral dihydropyrimidine dehydrogenase activity
11. Dihydropyrimidine dehydrogenase activity and mRNA expression in advanced gastric cancer analysed in relation to effectiveness of preoperative 5-fluorouracil-based chemotherapy
12. Colorectal tumours responding to 5-fluorouracil have low gene expression levels of dihydropyrimidine dehydrogenase, thymidylate synthase and thymidine phosphorylase
13. Clinicopathologic and prognostic significance of an angiogenic factor, thymidine phosphorylase, in human colorectal carcinoma
14. Pyrimidine nucleotide-metabolism in human colon carcinomas - Comparison of normal-tissues, primary tumours and xenografts
15. The activity and expression of thymidine phosphorylase in human solid tumours
16. Characterisation of dihydropyrimidine dehydrogenase in human colorectal tumours
17. Expression levels of thymidine phosphorylase and dihydropyrimidine dehydrogenase in various human tumour tissues
18. Regulation of dihydropyrimidine dehydrogenase in colorectal cancer
19. Dihydropyrimidine dehydrogenase activity in normal, inflammatory and tumour tissues of colon and liver in humans
20. Autoregulation of 5-fluorouracil metabolism
21. Dihydropyrimidine dehydrogenase activity and messenger RNA levels may be related to the antitumor effect of 5-fluorouracil on human tumour xenografts in nude mice
22. Expression of the angiogenic factor thymidine phosphorylase/platelet-derived endothelial cell growth factor in primary bladder cancers
23. Platelet-derived endothelial cell growth factor/thymidine phosphorylase concentrations differ in small cell and non-small cell lung cancer
24. Correlation between thymidine phosphorylase expression and prognosis in human renal cell carcinoma
25. Expression of the thymidine phosphorylase gene in epithelial ovarian cancer
26. Studies in 2-acetylaminofluorene carcinogenesis. III. The utilisation of uracil-2-14C by preneoplastic rat liver and rat hepatoma
27. Gene expression for dihydropyrimidine dehydrogenase and thymidine phosphorylase influences outcome in epithelial ovarian cancer